Stephen D Wiviott

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3366-73. 2005
  2. ncbi Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction
    Stephen D Wiviott
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:1553-8. 2006
  3. ncbi Update on lipid-lowering therapy and LDL-cholesterol targets
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Nat Clin Pract Cardiovasc Med 3:424-36. 2006
  4. ncbi Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 123:1854-63. 2011
  5. ncbi Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 152:627-35. 2006
  6. ncbi Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cardiol Clin 26:629-37. 2008
  7. ncbi The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Lipidol 17:626-30. 2006
  8. ncbi Clopidogrel response variability, resistance, or both?
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:18N-24N. 2006
  9. ncbi Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 108:905-11. 2011
  10. ncbi Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1626-36. 2008

Detail Information

Publications81

  1. ncbi Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3366-73. 2005
    ..Prasugrel (CS-747, LY640315), a novel potent thienopyridine P2Y(12) receptor antagonist, has the potential to achieve higher levels of inhibition of ADP-induced platelet aggregation than currently approved doses of clopidogrel...
  2. ncbi Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction
    Stephen D Wiviott
    TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 47:1553-8. 2006
    ..The purpose of this research was to evaluate the Thrombolysis In Myocardial Infarction risk index (TRI) to characterize the risk of death among patients with non-ST-segment elevation myocardial infarction (NSTEMI)...
  3. ncbi Update on lipid-lowering therapy and LDL-cholesterol targets
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Nat Clin Pract Cardiovasc Med 3:424-36. 2006
    ..We also consider the prospects for treatments in development and future goals...
  4. ncbi Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 123:1854-63. 2011
    ..The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD...
  5. ncbi Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infar
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 152:627-35. 2006
    ..TRITON-TIMI 38 is designed to compare prasugrel with clopidogrel in moderate to high-risk patients with acute coronary syndrome (ACS)...
  6. ncbi Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cardiol Clin 26:629-37. 2008
    ....
  7. ncbi The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Curr Opin Lipidol 17:626-30. 2006
    ..Concerns have been raised about the safety of this strategy. This review examines the safety and efficacy of treating to very low LDL-cholesterol...
  8. ncbi Clopidogrel response variability, resistance, or both?
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:18N-24N. 2006
    ..Point-of-care assays of platelet function may ultimately improve the ability of clinicians to modify therapy on the basis of response...
  9. ncbi Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 108:905-11. 2011
    ..In conclusion, these data indicate that use of prasugrel in a core clinical cohort that has been defined by regulatory action will maximize the benefit of prasugrel and limit the risk of adverse outcomes...
  10. ncbi Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1626-36. 2008
    ..We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38...
  11. ncbi A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1406-14. 2006
    ..We analyzed the design, implementation, and results of the two trials in an attempt to clarify the effects of early intensive statin therapy...
  12. ncbi Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 46:1411-6. 2005
    ..This study sought to evaluate the safety and efficacy of achieving very low calculated low-density lipoprotein (LDL) levels with intensive statin therapy...
  13. ncbi Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Stephen D Wiviott
    Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2923-32. 2007
    ..The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown...
  14. ncbi Safety and efficacy of achieving very low low-density lipoprotein cholesterol levels with rosuvastatin 40 mg daily (from the ASTEROID Study)
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Am J Cardiol 104:29-35. 2009
    ..Atheroma regression occurred in most patients and was not linked to the LDL cholesterol achieved...
  15. ncbi Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    J Am Coll Cardiol 44:783-9. 2004
    ..We sought to evaluate a simple risk index based on age and vital signs in a community sample of patients with ST-segment elevation myocardial infarction (STEMI)...
  16. ncbi Unstable angina and non-ST-segment elevation myocardial infarction: part I. Initial evaluation and management, and hospital care
    Stephen D Wiviott
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am Fam Physician 70:525-32. 2004
    ....
  17. ncbi Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  18. ncbi Clopidogrel resistance: a new chapter in a fast-moving story
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:3064-7. 2004
  19. ncbi Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, USA
    Lancet 371:1353-63. 2008
    ..We assessed the rate, outcomes, and prevention of ischaemic events in patients treated with prasugrel or clopidogrel with stents in the TRITON-TIMI 38 study...
  20. ncbi Cytochrome p-450 polymorphisms and response to clopidogrel
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 360:354-62. 2009
    ..Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function...
  21. ncbi Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  22. ncbi Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel
    Yuri B Pride
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    JACC Cardiovasc Interv 3:806-11. 2010
    ..This study sought to determine angiographic and clinical outcomes among patients with acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on 12-lead electrocardiogram (ECG)...
  23. ncbi Extent of ST-segment resolution after fibrinolysis adds improved risk stratification to clinical risk score for ST-segment elevation myocardial infarction
    James R Harkness
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 159:55-62. 2010
    ..We sought to determine whether STRes provides incremental risk stratification to the TIMI risk score...
  24. ncbi Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  25. ncbi Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1047-51. 2007
    ..On the basis of these findings, 1 death was prevented for every 95 patients treated with high-dose statin therapy for 2 years. The results of this pooled analysis provide further evidence for early intensive statin therapy after ACS...
  26. ncbi Clinical application of C-reactive protein across the spectrum of acute coronary syndromes
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02461, USA
    Clin Chem 53:1800-7. 2007
    ..The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS...
  27. ncbi Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Elliott M Antman
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2028-33. 2008
    ....
  28. ncbi Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON-
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, USA
    Circulation 123:2681-9. 2011
    ....
  29. ncbi Characteristics and in-hospital outcomes of patients with non-ST-segment elevation myocardial infarction and chronic kidney disease undergoing percutaneous coronary intervention
    Elias B Hanna
    Department of Medicine, Cardiovascular Section, Louisiana State University, New Orleans, Louisiana 70112, USA
    JACC Cardiovasc Interv 4:1002-8. 2011
    ..This specific population has not been evaluated previously...
  30. ncbi The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  31. ncbi Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
    ..We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of these drugs in healthy individuals...
  32. ncbi Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
    Michelle L O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 374:989-97. 2009
    ..Conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use, measures of platelet function, and clinical outcomes for patients treated with clopidogrel or prasugrel...
  33. ncbi Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program
    Michelle L O'Donoghue
    Cardiovascular Division and TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 34:36-43. 2012
    ..Although atopaxar increased the concentration of Lp-PLA(2) and IL-18, the clinical relevance of these findings remains unknown and warrants further investigation and validation...
  34. ncbi Vorapaxar in the secondary prevention of atherothrombotic events
    David A Morrow
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 366:1404-13. 2012
    ..Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1...
  35. ncbi Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:2358-62. 2009
    ....
  36. ncbi The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Am Coll Cardiol 54:678-85. 2009
    ..We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor...
  37. ncbi Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  38. ncbi Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
    Sean R Wilson
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 161:1147-55.e1. 2011
    ..Recent data have suggested a possible discordant adverse risk relationship in acute coronary syndrome (ACS). Therefore, we investigated the association between adiponectin and cardiovascular events in patients with ACS...
  39. ncbi A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2070-6. 2007
    ..To determine the relationship between a strategy of enoxaparin (ENOX), early ST-segment resolution (STRes), and clinical outcomes on patients with ST-segment elevation myocardial infarction (STEMI) after fibrinolysis...
  40. ncbi American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 125:577-83. 2012
    ..The prognostic implications of MI defined in the current era have not been well described...
  41. ncbi Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial
    Michelle L O'Donoghue
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 123:1843-53. 2011
    ..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...
  42. ncbi Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
    ..Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes...
  43. ncbi Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44
    Andrew L Frelinger
    Center for Platelet Research Studies, Division of Hematology Oncology, Children s Hospital Boston, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Thromb Haemost 106:219-26. 2011
    ..Patients who are hyper-responsive to ADP pre-treatment are more likely to be hyper-responsive to ADP on-treatment, which may be relevant to therapeutic strategies...
  44. ncbi Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  45. ncbi Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis
    Roberto R Giraldez
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Drugs 69:1433-43. 2009
    ....
  46. ncbi Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Massachusetts 02115, USA
    Circulation 114:281-8. 2006
    ..Retrospective analyses suggest that this risk may be modified with statin therapy. However, a role for hsCRP in monitoring the success of therapy remains uncertain...
  47. ncbi Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial
    Sabina A Murphy
    Department of Medicine, Cardiovascular Division, TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 29:2473-9. 2008
    ..We hypothesized that prasugrel would reduce not only first events but also recurrent primary endpoint events and therefore total events compared with clopidogrel...
  48. ncbi Rivaroxaban in patients with a recent acute coronary syndrome
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 366:9-19. 2012
    ..Since factor Xa plays a central role in thrombosis, the inhibition of factor Xa with low-dose rivaroxaban might improve cardiovascular outcomes in patients with a recent acute coronary syndrome...
  49. ncbi Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
    Alan D Michelson
    Department of Medicine, Children s Hospital Boston, Center for Platelet Research Studies, Division of Hematology Oncology, Boston, MA 02115, USA
    Eur Heart J 30:1753-63. 2009
    ..To examine the extent of platelet inhibition by prasugrel vs. clopidogrel in a TRITON-TIMI 38 substudy...
  50. ncbi Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials
    C Michael Gibson
    Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, Boston, MA 02115, USA
    Eur Heart J 25:1998-2005. 2004
    ..To determine the association of glomerular filtration rate (GFR) with clinical outcomes in the setting of non-ST-segment elevation acute coronary syndromes (NSTE-ACS)...
  51. ncbi Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS
    Kausik K Ray
    The TIMI Study Group and Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital Harvard Medical School, Boston, MA 02115, USA
    Eur Heart J 27:2310-6. 2006
    ..To assess the efficacy and safety of the achievement of the NCEP goal of LDL-C <1.8 mmol/L in elderly patients with ACS...
  52. ncbi Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy
    Willibald Hochholzer
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 162:518-26.e5. 2011
    ..The aims of this analysis were to evaluate the impact of smoking on the antiplatelet effect of clopidogrel and prasugrel and to test the potential interaction of smoking with the treatment effect of these drugs...
  53. ncbi Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--G
    Mitul B Kadakia
    TIMI Study Group, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    JACC Cardiovasc Interv 3:1166-77. 2010
    ..The aim of this study was to evaluate anticoagulant use patterns and bleeding risk in a contemporary population of patients with acute coronary syndrome...
  54. ncbi Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16
    Benjamin A Olenchock
    Department of Medicine, The Brigham and Women s Hospital, Boston, MA 02115, USA
    J Thromb Thrombolysis 26:79-84. 2008
    ..Recently, questions have been raised regarding the influence of pre-analytical and analytical conditions on measurement of sCD40L, and additional studies have had conflicting findings regarding the prognostic value of this marker...
  55. ncbi Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial
    Quynh A Truong
    Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am Heart J 157:673-9.e1. 2009
    ..We sought to evaluate whether TRI was predictive of long-term mortality and clinical events...
  56. ncbi Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  57. ncbi Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Circulation 119:2553-60. 2009
    ..The effect of CYP polymorphisms on the clinical outcomes in patients treated with prasugrel remains unknown...
  58. ncbi TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Am J Med 120:993-8. 2007
    ....
  59. ncbi Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
    Michelle O'Donoghue
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 114:e600-6. 2006
  60. ncbi Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Int J Cardiol 155:424-9. 2012
    ..We examined whether there were differential effects of prasugrel compared with clopidogrel in the multinational TRITON-TIMI 38 study...
  61. ncbi Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Clin Chim Acta 346:119-28. 2004
    ..Future research is needed to identify therapies of particular benefit for patients with ACS and natriuretic peptide elevation...
  62. ncbi Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes
    Robert W Yeh
    Department of Medicine, University of California, San Francisco, San Francisco, California, USA
    Am J Cardiol 100:1734-8. 2007
    ..In conclusion, thrombocytopenia is a significant correlate of adverse events in patients presenting with non-ST-elevation ACS treated with either enoxaparin or UFH...
  63. ncbi Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial
    Robert P Giugliano
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2398-407. 2007
    ..We sought to evaluate the safety and efficacy of recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with non-ST-segment elevation acute coronary syndrome (nSTE-ACS)...
  64. ncbi Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality
    C Michael Gibson
    TIMI Study Chairman s Office, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
    J Am Coll Cardiol 42:1535-43. 2003
    ..We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis...
  65. ncbi Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
    Yuri B Pride
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    Am Heart J 158:e21-6. 2009
    ..Whether this benefit extends to patients undergoing PCI without stent implantation is unknown...
  66. ncbi Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    Christopher P Cannon
    The TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 156:826-32. 2008
    ....
  67. ncbi Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE
    Patricia Tung
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 103:1056-60. 2009
    ..This variability affected achievement of National Cholesterol Education Program goals and may affect management decisions based on season of collection...
  68. ncbi Clinical applications of antiplatelet therapy
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:130-46; quiz 148-9. 2006
    ..Nonresponsiveness to clopidogrel treatment has been suggested as a risk factor for the occurrence of ischemic events and stent thrombosis...
  69. ncbi Effect of prior stroke on the use of evidence-based therapies and in-hospital outcomes in patients with myocardial infarction (from the NCDR ACTION GWTG registry)
    Farhad Abtahian
    Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts
    Am J Cardiol 107:1441-6. 2011
    ..Despite this, previous stroke patients are less likely to receive guideline-based MI therapies...
  70. ncbi New antiplatelet therapies for acute coronary syndromes
    Jonathan D Rich
    Cardiovascular Division, Brigham and Women s Hospital, TIMI Study Group, Boston, MA 02115, USA
    Curr Cardiol Rep 9:303-11. 2007
    ..Three antiplatelet agents currently under investigation (prasugrel, AZD6140, and cangrelor) in clinical trials for the treatment of ACS appear promising...
  71. ncbi Comparison of outcomes in patients aged <75, 75 to 84, and ≥ 85 years with ST-elevation myocardial infarction (from the ACTION Registry-GWTG)
    Daniel E Forman
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 106:1382-8. 2010
    ..Disparities in process of care and co-morbidity may explain these observational findings. Whether efforts to optimize patient selection and initiate reperfusion therapy can improve outcomes in the oldest old with STEMI is unknown...
  72. ncbi Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary
    Laura Mauri
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 160:1035-41, 1041.e1. 2010
    ..Although current clinical practice guidelines recommend 12-month treatment after drug-eluting stent placement, even longer durations may prevent thrombotic events...
  73. ncbi Therapeutic goals for effective platelet inhibition: a consensus document
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Rev Cardiovasc Med 7:214-25. 2006
    ..These novel agents such as prasugrel, AZD6140, and cangrelor are in advanced stages of clinical development for potential use in patients with coronary artery disease...
  74. ncbi Unstable angina and non-ST-segment elevation myocardial infarction: part II. Coronary revascularization, hospital discharge, and post-hospital care
    Stephen D Wiviott
    Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am Fam Physician 70:535-8. 2004
    ....
  75. ncbi Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas Southwestern Medical Center, Dallas 75390 9047, USA
    JAMA 292:1307-16. 2004
    ..Limited data are available evaluating how the timing and intensity of statin therapy following an acute coronary syndrome (ACS) event affect clinical outcome...
  76. ncbi Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, 5323 Harry Hines Blvd, Rm HA 9 133, UT Southwestern Medical Center, Dallas, TX 75390 9047, USA
    Eur Heart J 25:1688-94. 2004
    ..However, less is known about the relative merits of these two forms of heparin in patients receiving concomitant glycoprotein IIb/IIIa inhibitors...
  77. ncbi Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial
    James A de Lemos
    Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 98:739-42. 2006
    ..In conclusion, these observations represent missed opportunities for primary and secondary prevention and highlight the need for assessment of patient risk and better adherence to existing prevention guidelines...
  78. ncbi A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38
    Stephen D Wiviott
    Am J Cardiol 101:1367-70. 2008
  79. ncbi A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
    John T Brandt
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Am Heart J 153:66.e9-16. 2007
    ..Thienopyridines are prodrugs, metabolized in vivo to active metabolites that inhibit the platelet P2Y12 adenosine diphosphate (ADP) receptor...
  80. ncbi Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial
    James A de Lemos
    Donald W Reynolds Cardiovascular Clinical Research Center, UT Southwestern Medical Center, Dallas, Texas 75390 9047, USA
    J Am Coll Cardiol 50:2117-24. 2007
    ..This study sought to determine whether the novel biomarker monocyte chemoattractant protein (MCP)-1 adds prognostic value to standard risk assessment tools and biomarkers after acute coronary syndromes (ACS)...
  81. ncbi Antiplatelet agents make a comeback in ST-elevation myocardial infarction
    Stephen D Wiviott
    Am Heart J 154:603-6. 2007